Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
- Submitting institution
-
The University of Sheffield
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 8283
- Type
- D - Journal article
- DOI
-
10.1200/jco.20.01800
- Title of journal
- Journal of Clinical Oncology
- Article number
- -
- First page
- 4064
- Volume
- 38
- Issue
- 34
- ISSN
- 0732-183X
- Open access status
- Not compliant
- Month of publication
- October
- Year of publication
- 2020
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
24
- Research group(s)
-
B - Cancer
- Citation count
- 0
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- (a) The author made a substantial contribution to the conception and design of the study; to the organisation of the conduct of the study; to carrying out the study; and to analysis and interpretation of study data. (b) The author helped draft the output.
- Non-English
- No
- English abstract
- -
